AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01889563 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Exercise Training Program Exercise
Description: Physical Exercise Training Program Exercise training was conducted in three times a week, during 12 weeks at high-intensity targets. Each session consisted of a five minute warm up (walking) at 2 km/h and 30 minutes with an intensity targets set at 70% of the peak speed rate. The increase of intensity was 0.5Km/h when the patient scored less than 4 point of Borg scale (moderate to intense effort) during each session. All evaluations were done at 6th week, in order to analyze the progression of outcomes and exactly adjust the intensity of training.
Study NCT02244528 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil
Study NCT02440399 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol hydrochloride
Description: Please see arm description
Study NCT02440399 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: Please see arm description
Study NCT02440399 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol
Study NCT02440399 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac
Study NCT04663620 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Saving Babies Lives Programme
Description: Comprehensive neonatal healthcare package
Study NCT04663620 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: No Saving Babies Lives Programme
Description: No comprehensive neonatal healthcare package
Study NCT01912040 — intervention group
Intervention type: DRUG
Intervention: Administration of 123Iodine MIBG
Description: Patients will be administered the locally produced 123 Iodine MIBG
Study NCT02758379 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Shockwave Coronary Lithoplasty System
Description: Lithotripsy shockwaves are used to fracture calcified lesions in the coronary arteries
Study NCT01908738 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paracervical block with 1%lidocaine
Description: To determine effectiveness of paracervical block, lidocaine spray and only oral analgesic drugs for pain relief during endometrial biopsy.~Pain score(NRS) immediately after procedure and 15 minutes Group 1(1%Lidocaine) Group 2(10%Lidocaine spray) Control group(Placebo) Pain score immediately Pain score 15 minutes
Study NCT01908738 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: paracervical block with 1%lidocaine
Description: To determine effectiveness of paracervical block, lidocaine spray and only oral analgesic drugs for pain relief during endometrial biopsy.~Pain score(NRS) immediately after procedure and 15 minutes Group 1(1%Lidocaine) Group 2(10%Lidocaine spray) Control group(Placebo) Pain score immediately Pain score 15 minutes
Study NCT02440399 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAB. Percocet (Oxycodone 5MG/Paracetamol 325 MG)
Study NCT01301001 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo oral capsule
Description: Placebo 2 capsules am and 3 capsules pm
Study NCT01301001 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Placebo 2 capsules am and 3 capsules pm
Study NCT01301001 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin
Description: Gabapentin 1200 mg am and 1800 mg pm
Study NCT01301001 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gabapentin
Description: Gabapentin 1200 mg am and 1800 mg pm
Study NCT00862901 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CLIPT patch
Description: A Diomed laser will deliver 630nm (red spectrum) light through a Fiber optic Patch. The Fiber Optic Patch will be compatible with the laser, delivering light to a designated region on the patient's skin. Patients will receive a single intravenous injection of Photofrin (0.8mg/kg body weight) 36 - 48 hours prior to the CLIPT procedure. PDT will be delivered over 24 hours for the dose of each arm. Patients will be enrolled in sequential cohorts of six, at increasing laser intensity until the maximum tolerated dose is reached.
Study NCT01908738 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10%lidocaine spray
Study NCT01908738 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 10%lidocaine spray
Study NCT01445054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 111Indium CHX-A
Description: 111Indium CHX-A will be administered intravenously over a 10-15 minute period using an intravenous catheter
Study NCT03137576 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Paravertebral Block (PVB)
Description: PVB consists in the injection of low concentration Ropivacaine (30 ml, 0.3%) in the paravertebral space (defined by the anterior aspect of the ribs, the vertebral body and the parietal pleura. The space is identified under ultrasonographic guidance by a dedicated Anesthesiologist.
Study NCT03137576 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Erector Spinae Plane Block (ESPB)
Description: ESPB consists in the injection of low concentration Ropivacaine (30 ml, 0.3%), in the anatomical plane between the Erector Spinae muscles and deeper surface of Rhomboid muscle. The space is identified under ecographic guidance, laterally to the spinous process of T5. The diffusion of the anesthetic solution along the space can be echographically appreciated.
Study NCT01683500 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: shock wave therapy with Modulith SLK (Storz)
Description: Three sessions with shock wave therapy, interval of one week.
Study NCT02202720 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: Short term sedation with sevoflurane in ICU
Study NCT04520451 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rilzabrutinib
Description: oral tablet
Study NCT04520451 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucocorticoids
Description: oral tablet or capsule
Study NCT04520451 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucocorticoids
Description: oral tablet or capsule
Study NCT01557816 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen
Description: Naproxen for 7 days (3 days at 250 mg BID followed by 4 days at 500 mg BID) during either of the 2 treatment periods.
Study NCT01557816 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Naproxen
Description: Naproxen for 7 days (3 days at 250 mg BID followed by 4 days at 500 mg BID) during either of the 2 treatment periods.
Study NCT01557816 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo for seven days given BID during either of the 2 treatment periods.
Study NCT01557816 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Placebo
Description: Placebo for seven days given BID during either of the 2 treatment periods.
Study NCT01856660 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low-Carbohydrate Diet
Description: Participants are provided with a 6-month standard lifestyle intervention where carbohydrate intake is limited to 50 g/day. There is no calorie restriction for participants following the Low-Carbohydrate diet. Gradual increase in physical activity across the trial to > 40 min per day, 5 times/week.
Study NCT01856660 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low-fat Diet
Description: Participants are provided with a 6-month standard lifestyle intervention. They will follow an energy restricted, low-fat diet where the daily energy consumption target is 1,200- 1,500 kilocalories/d. The fat intake target is 28% or less of daily kilocalories. Gradual increase in physical activity until participants are active at least 40 min per day, 5 times/week.
Study NCT01216280 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo capsule
Description: 2 x 10 mg placebo capsules administered orally with water, b.i.d.
Study NCT01216280 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10 mg Natura-alpha capsule and 10 mg placebo capsule
Description: 10 mg Natura-alpha capsule and 10 mg placebo capsule administered orally with water, b.i.d.
Study NCT01216280 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2 x 10 mg Natura-alpha capsules
Description: 2 x 10mg Natura-alpha capsules administered orally with water, b.i.d.
Study NCT06251830 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: MRI exam with Magnetic Resonance Fingerprinting
Description: Acquisition of MRI data with technique Magnetic Resonance Fingerprinting
Study NCT00887081 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-IFN alpha2a or PEG-IFN alpha2b and Ribavirin
Description: PEG-IFN alpha2a 180 mcg weekly or PEG-IFN alpha2b 1.5 mcg/kg of body weight weekly plus ribavirin 800-1200 mg daily according to body weight.
Study NCT00728416 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone furoate nasal spray (MFNS)
Description: MFNS 50 mcg/spray: two sprays in each nostril once daily (ie, 200 mcg QD) for 15 days
Study NCT00728416 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo nasal spray
Description: Matching placebo nasal spray: 2 sprays in each nostril once daily for 15 days
Study NCT04901897 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: kalifilcon A
Description: kalifilcon A daily disposable contact lens
Study NCT04901897 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: delefilcon A
Description: DAILIES TOTAL1® (delefilcon A) daily disposable contact lenses
Study NCT00656461 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MKC-1
Description: 30 mg and 100 mg capsules, dosed BID daily on a continuous schedule
Study NCT01095705 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional procedure
Description: Local anaesthesia (Lidocaïne)
Study NCT01095705 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional procedure + Hypnosis
Description: Local anaesthesia (Lidocaïne) + Hypnosis (20 minutes)
Study NCT02717013 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules containing calcium lactate similar to the HMB capsules.
Study NCT02717013 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: HMB
Description: HMB capsules supplying 3 grams per day of calcium beta-hydroxyl-beta-methylbutyrate.
Study NCT03393299 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: STOPP/START criteria
Description: software which helps to do the drug reconciliation
Study NCT03701100 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tDCS
Description: tDCS
Study NCT04901897 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: senofilcon A
Description: Acuvue Oasys® 1-Day with HydraLuxe™ (senofilcon A) daily disposable contact lens
Study NCT03063073 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine Injection [Precedex]
Description: ultrasound guided modified Pecs block with 30 mL of 0.25% bupivacaine (markyrene R sigma -Tec, Egypt) plus (1 µg/kg) Dexmedetomidine Injection \[Precedex\]
Study NCT03063073 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Study NCT03063073 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bupivacaine
Study NCT00939263 — intervention group
Intervention type: OTHER
Intervention: assessment of disease activity using the EEsAI
Description: disease activity index
Study NCT03613428 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Dose escalation up to 80 mg administered orally
Study NCT03613428 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: 1.4 mg/m2 i.v. weekly for 4 weeks
Study NCT03613428 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 1 mg/kg orally 5 consecutive days per week for 4 weeks.
Study NCT02478398 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Short ragweed pollen allergen extract
Description: One sublingual tablet containing 12 units of Amb a 1-U, once daily (QD) for up to 35 weeks.
Study NCT02478398 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One placebo sublingual tablet, QD for up to 35 weeks.
Study NCT02478398 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Self-injectable epinephrine
Description: Intramuscular (IM) injection with suggested doses of 0.15 mg for participants weighing 15-30 kg (33-66 pounds) or 0.3 mg for participants weighing ≥30 kg (≥66 pounds), as needed for severe allergic reactions. Epinephrine was only provided in countries/study sites where it was a regulatory requirement.
Study NCT02478398 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Self-injectable epinephrine
Description: Intramuscular (IM) injection with suggested doses of 0.15 mg for participants weighing 15-30 kg (33-66 pounds) or 0.3 mg for participants weighing ≥30 kg (≥66 pounds), as needed for severe allergic reactions. Epinephrine was only provided in countries/study sites where it was a regulatory requirement.
Study NCT02478398 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Albuterol/Salbutamol
Description: Inhalation of albuterol 90 mcg/puff or salbutamol 100 mcg/puff metered dose inhaler (MDI), as needed as asthma rescue medication for those participants with asthma
Study NCT02478398 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol/Salbutamol
Description: Inhalation of albuterol 90 mcg/puff or salbutamol 100 mcg/puff metered dose inhaler (MDI), as needed as asthma rescue medication for those participants with asthma
Study NCT02478398 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Loratadine
Description: 5 mg (1 mg/mL syrup or 5 mg tablet) for participants 5 years old or 10 mg (1 mg/mL syrup or 10 mg tablet) for participants 6 to 17 years old, as needed for rhinoconjunctivitis symptoms
Study NCT02478398 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loratadine
Description: 5 mg (1 mg/mL syrup or 5 mg tablet) for participants 5 years old or 10 mg (1 mg/mL syrup or 10 mg tablet) for participants 6 to 17 years old, as needed for rhinoconjunctivitis symptoms
Study NCT02478398 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Olopatadine
Description: Opthalmic solution, 1 drop (0.1%) per affected eye twice daily (BID), as needed for rhinoconjunctivitis symptoms
Study NCT02478398 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olopatadine
Description: Opthalmic solution, 1 drop (0.1%) per affected eye twice daily (BID), as needed for rhinoconjunctivitis symptoms
Study NCT02478398 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Mometasone furoate monohydrate
Description: Intranasal spray, at doses of 1 spray (50 mcg/ spray) per nostril for participants 5 to 11 years old or 2 sprays (50 mcg/spray) per nostril for participants 12 to 17 years old, as needed for rhinoconjunctivitis symptoms
Study NCT02478398 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone furoate monohydrate
Description: Intranasal spray, at doses of 1 spray (50 mcg/ spray) per nostril for participants 5 to 11 years old or 2 sprays (50 mcg/spray) per nostril for participants 12 to 17 years old, as needed for rhinoconjunctivitis symptoms
Study NCT03230201 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lymph node dissection
Description: Lymph node dissection during radical nephroureterectomy
Study NCT02764021 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Carbohydrate-Restricted Diet
Description: Macronutritional composition: Carbohydrate 30 E%, Protein 30 E%, Fat 40 E%
Study NCT02764021 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Standard Antidiabetic Diet
Description: Macronutritional composition: Carbohydrate 50 E%, Protein 13 E%, Fat 17 E%
Study NCT04665882 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Axillary surgery based on lymphedema prediction nomogram
Description: Based on the intraoperative lymphedema prediction nomogram, individualized treatment was recommended to breast cancer patients with different level of risk. For patients with low possibility of developing breast cancer related lymphedema, it was not necessary to preserve arm lymphatics. While the breast cancer patients who were performed mastectomy and ALND with 28 kg/m2 prepared to receive taxane-based chemotherapy, supraclavicular and infraclavicular radiotherapy, according to the established intraoperative nomogram, the proportion of the arm lymph flow above the axillary vein needed to exceed 52%. Otherwise, the arm lymphatics should be identified and preserved.
Study NCT01153464 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Recovery Support Counseling
Description: Telephone based recovery support provided by paraprofessionals at the City of Philadelphia's Behavioral Health Department. Calls are once weekly for 8 weeks, then step down to every other week for the remainder of the year of study participation. Call frequency can be increased as a result of a rise in risk factor/protective factor ratio.
Study NCT04172129 — intervention group
Intervention type: DEVICE
Intervention: Total Hip Arthroplasty
Study NCT03123185 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tablet and solution formulation
Study NCT03123185 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 705564 (Test)
Description: Fed state
Study NCT03123185 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 705564 (Reference)
Description: Fasting state
Study NCT03243188 — intervention group
Intervention type: OTHER
Intervention: Qualitative interview
Description: Qualitative data will be obtained through semi-structured interviews with adults with cancer and palliative care needs. Patients will be invited to bring their carer to the interview. EG will conduct and transcribe up to 30 audio-recorded semi-structured interviews, which will be carried out at the patient's preferred location (either at home, over the phone, or in a pre-booked room at St Joseph's Hospice). EG will ask questions relating to sociodemographic data (recording this on the Personal Information Sheet) prior to starting the interview.
Study NCT02491450 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Heterosofir
Description: 1 tablet contains 400 mg sofosbuvir
Study NCT02491450 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sovaldi
Description: 1 tablet contains 400 mg sofosbuvir
Study NCT04129801 — intervention group
Intervention type: OTHER
Intervention: Isokinetic Dynamometer
Description: Participants then executed two series of four uninterrupted repetitions of Ext and Flex of both legs, first with the dominant member and subsequently with the non-dominant member, at an angular velocity of 60o/s, with a 60-second interval between series.
Study NCT04129801 — intervention group
Intervention type: OTHER
Intervention: Bioimpedance
Description: Bioimpedance The BC measurements as FM (% and kg), FFM (% and kg), will be obtained by the indirect noninvasive method of electrical bioimpedance (BIA) 230, 2.0, (Biospace Seoul, Korea). Those evaluated will be standing and positioned on the platform electrodes, barefoot and with their arms extended with their hands on the two supports (electrodes).
Study NCT02116062 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: 1. Amniotic membrane transplantation on the cornea with the Da Vinci Si HD© robot (Inlay or overlay technique)
Study NCT02116062 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Pterygium removal and autograft of the conjunctiva with the Da Vinci Si HD© robot (Kenyon technique)
Study NCT02116062 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Penetrating keratoplasty using Baron trephine and nylon stitches with the Da Vinci Si HD© robot
Study NCT02313272 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated Stereotactic Irradiation (HFSRT)
Description: Radiation therapy treatment (FSRT) which will be given to participants over 5 days.
Study NCT02313272 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Dose Escalation: The dose of pembrolizumab will be escalated per schema in a 3+3 fashion. The starting dose (i.e., dose level 1) will be 100 mg.~Dose Expansion: The pembrolizumab dose used in the dose expansion cohort will be maximum tolerated dose (MTD) determined from the dose escalation phase.
Study NCT02313272 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Initial cycle of bevacizumab must start within 10 days of registering to the trial. It will be given concurrent with radiation therapy. Bevacizumab will be administered intravenously at a dose of 10 mg/kg every 2 weeks. Doses will be adjusted if there is a > 10% change in weight.
Study NCT03313765 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI)
Description: Brief MI intervention
Study NCT03313765 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard-of-care
Description: Standard-of-care education and counseling
Study NCT00500110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 30 mg/m\^2 by vein (IV) Weekly Over 60 Minutes on Days 1, 8, 15, and 22. This will be followed by 2 weeks with no docetaxel.
Study NCT00500110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib Mesylate
Description: 600 mg by mouth (PO) Daily x 42 Days.
Study NCT00500110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide
Description: Hormone injections given every other month or every 3 months, as determined by the doctor.